查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1847913

驱虫药市场（依药物类别、动物种类、给药途径、剂型及销售管道）——2025-2032 年全球预测

Anthelmintic Drugs Market by Drug Class, Animal Type, Route Of Administration, Formulation, Sales Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年驱虫药市场规模将成长至 67.4 亿美元，复合年增长率为 8.26%。

主要市场统计数据
基准年2024年 35.7亿美元
预计2025年 38.6亿美元
预测年份：2032年 67.4亿美元
复合年增长率（%） 8.26%

全面说明驱虫药的治疗重要性、临床压力以及影响人类和动物健康治疗方法的商业性要求。

驱虫药是兽医和人类寄生虫疾病管理的基石，在动物健康、公共卫生和农业生产力方面带来显着效益。这些疗法涵盖多种针对线虫、绦虫和颤动虫的化学类型和给药方法，其合理应用对于维护动物福利和食品安全至关重要。临床医生、生产者和公共卫生官员日益面临寄生虫抗药性不断演变、监管预期不断变化以及优化治疗效果并最大程度降低环境和残留问题的压力等复杂因素的相互作用。

在此背景下，相关人员需要简洁的、基于证据的分析来指导其临床和商业优先事项。本报告整合了当前的科学趋势、监管发展和分销管道动态，以帮助决策者协调其开发平臺、筹资策略和上市倡议。透过将临床背景与营运现实相结合，本报告为深入了解市场驱动力以及製造商、经销商和政策制定者可用的战术性选项奠定了基础。

进化压力、科学创新和监管的融合正在重塑驱虫治疗的商业策略和管理模式

驱虫药物领域正在发生重大变化，这得益于分子类别的创新、抗药性模式的不断增加以及监管和永续性考虑的融合。新的化学成分和製剂技术正在扩展治疗套件，使其具有更长的药效持续时间、更好的偏好以及替代的给药方式，从而更好地满足最终用户的需求。同时，基因组监测和现场诊断揭示了异质性抗药性的出现，这需要有针对性的管理计划和针对特定部位的治疗流程。

治疗模式也在不断调整，製造商投资于附加价值服务，例如诊断主导的治疗建议和针对大规模畜牧养殖的批量供应解决方案。法律规范日益重视残留监测、环境风险评估和严格的产品生命週期数据，从而推动更早、更整合的监管策略工作流程。这种转变凸显了市场参与企业需要摆脱以产品为中心的规划，提供将治疗效果与可证明的管理和永续性结合的综合服务。因此，药物开发商、诊断公司和分销网络之间的伙伴关係正成为该领域竞争定位的核心特征。

2025 年推出的贸易政策调整创造了持续的供应链和采购需求，影响製造决策和商业定价动态

美国自2025年起实施的关税变化的累积影响，为整个驱虫药价值链的供应链优化、筹资策略和定价模式带来了新的考量。进口关税及相关贸易措施提高了某些来自国际製造地的活性原料药和成品药的到岸成本，迫使采购团队重新评估供应商的多样性，并加快替代製造商的资格认定。同时，分销合作伙伴和动物用药品批发商也重新评估了其库存和对冲策略，以减轻利润压力并保持关键治疗产品供应的连续性。

这些发展趋势也促使企业认真审视其区域製造投资和近岸外包策略，以降低关税波动风险，并提高对当地监管核准的应对力。拥有垂直整合和灵活契约製造能力的企业找到了稳定价格和交货时间的机会，而规模较小的企业在与通路合作伙伴的谈判中则面临着日益复杂的局面。为此，商务团队正在改进合约条款，探索关税分类优化，并深化与海关和贸易顾问的合作，以确保合规性，同时确保客户获得必需品。

细緻的细分洞察，包括药理类别、动物群、给药途径、製剂类型和渠道行为，揭示商业化的目标机会

细分领域的动态揭示了差异化的临床和商业性轨迹，需要针对不同的治疗类别、动物群、给药途径、剂型和销售管道製定有针对性的策略。在药物类别中，该领域的特点是传统的苯并咪唑酮类药物，它们在许多方案中继续充当骨干药物；咪唑并噻唑和四氢嘧啶类药物，它们对特定寄生虫群体具有互补的药效动力学特性；以及大环内酯类药物，因其频谱活性和长效製剂而备受推崇。每类药物都有不同的动态风险，需要製定管理计划，使给药方案与诊断数据一致。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 开发伊维菌素和奥克太尔联合治疗来对抗抗药性土源性蠕虫
  • 引入照护现场分子诊断技术快速检测牲畜多重抗药性蠕虫感染疾病
  • 植物来源植物化学驱虫剂作为水产养殖管理的永续替代品的出现
  • 在盘尾丝虫病和淋巴丝虫病共同流行的地区进行综合性群众性药物管理宣传活动
  • 投资奈米製剂技术以提高苯并咪唑驱虫药的生物有效性和功效
  • 旨在最大程度减少环境中药物残留的新型大环内酯类似物的监管核准途径
  • 利用药物基因体学数据扩展精准剂量演算法，以优化儿科族群的驱虫治疗

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 驱虫药市场（依药物类别）

  • 苯并咪唑
  • 咪唑并噻唑和四氢嘧啶
  • 大环内酯

第九章 驱虫药市场（依动物类型）

  • 伴侣动物
    • 猫
    • 狗
  • 食用动物
    • 牛
    • 家禽
    • 绵羊和山羊
    • 猪
  • 人类
    • 成人
    • 孩子们

第十章 驱虫药市场（依给药途径）

  • 口服
  • 肠外
  • 话题

第 11 章。按配方分類的驱虫药市场

  • 注射
  • 口服悬浮液
  • 药片

第 12 章 驱虫药市场（依销售管道）

  • 网路药局
  • 零售药局
  • 兽药经销商
  • 兽医医院和诊所

第十三章 各地区驱虫药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章 驱虫药市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各国驱虫药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Merck & Co., Inc.
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale SA
    • Virbac SA
    • Dechra Pharmaceuticals PLC
    • Norbrook Laboratories Limited
    • Aden Healthcare
    • Bayer AG
    • Cipla Limited
    • Anikem Laboratories
Product Code: MRR-FB6C9E792F81

The Anthelmintic Drugs Market is projected to grow by USD 6.74 billion at a CAGR of 8.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.57 billion
Estimated Year [2025] USD 3.86 billion
Forecast Year [2032] USD 6.74 billion
CAGR (%) 8.26%

Comprehensive orientation to anthelmintic therapeutic importance, clinical pressures, and commercial imperatives shaping treatment approaches across human and animal health

Anthelmintic drugs remain a cornerstone of veterinary and human parasitic disease management, delivering measurable benefits across animal health, public health, and agricultural productivity. The therapeutic category encompasses a range of chemotypes and administration approaches that target nematodes, cestodes, and trematodes, and their appropriate deployment is critical to sustaining animal welfare and food safety. Clinicians, producers, and public health authorities increasingly face a complex interplay of evolving parasite resistance, shifting regulatory expectations, and pressure to optimize therapeutic efficacy while minimizing environmental and residue concerns.

Against this backdrop, stakeholders require concise, evidence-driven analysis that frames clinical and commercial priorities. This report synthesizes current scientific developments, regulatory trends, and distribution channel dynamics to enable decision-makers to align research and development pipelines, procurement strategies, and market access initiatives. By integrating clinical context with operational realities, this introduction sets the stage for deeper examination of market-moving forces and tactical options available to manufacturers, distributors, and policy makers.

Evolutionary pressures, scientific innovations, and regulatory convergence are reshaping commercial strategies and stewardship models across anthelmintic therapeutics

The landscape for anthelmintic drugs is undergoing transformative shifts driven by innovation in molecular classes, rising resistance patterns, and the convergence of regulatory and sustainability agendas. Novel chemistries and formulation technologies are expanding the therapeutic toolkit, enabling longer duration of action, improved palatability, and alternative delivery modalities that better match end-user needs. Concurrently, genomic surveillance and field-level diagnostics are revealing heterogeneous resistance emergence that requires targeted stewardship programs and region-specific treatment algorithms.

Commercial models are adapting as well, with manufacturers investing in value-added services such as diagnostic-driven treatment recommendations and bundled supply solutions for large livestock operations. Regulatory frameworks are increasingly emphasizing residue monitoring, environmental risk assessment, and rigorous product lifecycle data, prompting earlier and more integrated regulatory strategy workstreams. These shifts underscore the need for market participants to pivot from product-centric plans to integrated service offerings that combine therapeutic efficacy with demonstrable stewardship and sustainability credentials. As a result, partnerships between pharmaceutical developers, diagnostic firms, and distribution networks are becoming a central feature of competitive positioning in this sector.

Trade policy adjustments introduced in 2025 have created sustained supply chain and sourcing imperatives that influence manufacturing decisions and commercial pricing dynamics

The cumulative impact of tariff changes initiated in the United States during 2025 has introduced new considerations for supply chain optimization, sourcing strategy, and pricing models across the anthelmintic drugs value chain. Import duties and related trade measures have increased landed costs for certain active pharmaceutical ingredients and finished formulations sourced from international manufacturing hubs, prompting procurement teams to reassess supplier diversity and to accelerate qualification of alternative manufacturers. In parallel, distribution partners and veterinary wholesalers have revisited inventory and hedging practices to mitigate margin pressure and to preserve continuity of supply for critical therapeutic lines.

These developments have also incentivized a deliberate reconsideration of regional manufacturing investments and nearshoring strategies to reduce exposure to tariff volatility and to enhance responsiveness to local regulatory approvals. Firms with greater vertical integration or flexible contract manufacturing capabilities have found opportunities to stabilize pricing and delivery, while smaller companies face heightened negotiation complexity with channel partners. In response, commercial teams are refining contractual terms, exploring tariff classification optimizations, and deepening collaboration with customs and trade advisors to navigate compliance while preserving customer access to essential products.

Granular segment insights across pharmacological classes, animal cohorts, administration routes, formulation types, and channel behaviors reveal targeted opportunities for commercialization

Segment-level dynamics reveal differentiated clinical and commercial trajectories that require targeted strategies across drug classes, animal cohorts, administration routes, formulation types, and sales channels. Based on drug class, the field is characterized by traditional benzimidazoles which continue to serve as backbone agents in many protocols, imidazothiazoles and tetrahydropyrimidines that offer complementary pharmacodynamic profiles for specific parasite groups, and macrocyclic lactones which are prized for broad-spectrum activity and long-acting formulations. Each class presents distinct resistance risks and requires stewardship planning that aligns dosing regimens with diagnostic data.

Based on animal type, the commercial and clinical landscapes diverge meaningfully. Companion animals prioritize safety, taste, and convenient administration, with companion animal cohorts further differentiated into cats and dogs that have unique tolerability and product preference patterns. Food producing animals focus on production economics and residue compliance, with cattle, poultry, sheep and goat, and swine exhibiting varied parasite exposure and management frameworks that drive treatment frequency and product choice. The human segment requires rigorous safety and regulatory oversight with adult and pediatric subpopulations demanding tailored dosing and formulation considerations. Based on route of administration, product selection and adoption hinge on oral therapies favored for ease of use, parenteral options chosen for bioavailability and controlled delivery, and topical preparations selected for localized application and owner convenience.

Based on formulation, injectable preparations deliver reliable plasma concentrations for systemic infections, oral suspensions meet needs for flexible dosing across weight ranges, and tablets remain a staple where stability and dosing accuracy are paramount. Based on sales channel, adoption and access are shaped by online pharmacies that expand reach and convenience, retail pharmacies that serve human and companion animal markets, veterinary distributors that bridge manufacturers and clinical end users, and veterinary hospitals and clinics that serve as primary points of care and influence repeat purchase behavior. Understanding these intersecting segment dynamics enables more precise product positioning, pricing strategies, and lifecycle management decisions that reflect both clinical performance and customer preferences.

Regional epidemiology, regulatory diversity, and distribution maturity across the Americas, EMEA, and Asia-Pacific create distinct pathways for market access and product adoption

Regional dynamics in anthelmintic therapeutics vary by epidemiology, regulatory requirements, and distribution infrastructure, shaping differentiated priorities for manufacturers and suppliers. The Americas region exhibits mature distribution frameworks, widespread veterinary practice networks, and increasing demand for innovation in companion animal care alongside large-scale livestock production systems that prioritize productivity and residue compliance. In this region, integrated service models and diagnostic-driven treatment protocols are gaining traction to optimize therapeutic outcomes and to address resistance concerns.

Europe, Middle East & Africa present a complex mosaic of market conditions where stringent regulatory oversight in parts of Europe coexists with variable access and infrastructure constraints across other countries. This diversity requires adaptable market access strategies that balance regulatory rigor, affordability, and targeted education initiatives to support appropriate use. In several countries within this geography, environmental considerations and sustainability reporting are becoming prominent purchase criteria, influencing formulation development and post-market monitoring.

Asia-Pacific encompasses high-growth livestock sectors, an expanding companion animal market, and diverse regulatory regimes that range from highly structured to evolving frameworks. Rapid adoption of digital distribution channels and a growing appetite for value-added services are notable across the region. Manufacturers operating here must navigate heterogeneous reimbursement and procurement landscapes while leveraging regional manufacturing capacity to enhance supply resilience and to meet local demand patterns.

Competitive landscape shaped by legacy pharmaceutical strengths, specialized innovation, and collaborative models that integrate diagnostics, manufacturing flexibility, and channel influence

Competitive dynamics among leading organizations in the anthelmintic space reflect a mix of legacy pharmaceutical capabilities, targeted innovation investments, and strategic partnerships. Established animal health pharmaceutical firms continue to leverage extensive clinical trial experience, regulatory know-how, and deep distribution networks to sustain presence in both livestock and companion animal segments. At the same time, specialist biotech and smaller innovators are advancing novel molecules, reformulations, and diagnostic-integrated offerings that aim to address resistance hotspots and to create differentiated value propositions.

Partnerships between diagnostics providers and therapeutic developers are emerging as a critical vector for competitive advantage, as real-world diagnostic data enables more precise treatment algorithms and supports stewardship narratives. Contract manufacturing organizations with flexible capacity and quality systems are increasingly strategic allies for companies seeking to scale production or to diversify geographic sourcing. Additionally, distributors and veterinary service networks that invest in training and digital engagement are gaining influence over prescribing patterns and can accelerate uptake of new products through bundled service models and clinician education initiatives.

Actionable priorities for manufacturers and distributors to align therapeutic innovation, stewardship programs, and supply resilience with channel-specific commercialization tactics

Industry leaders should pursue a multilayered approach that aligns product innovation with stewardship, supply resilience, and channel-centric commercialization. Prioritizing diagnostic-enabled treatment paradigms will both extend therapeutic lifespans and create opportunities for premium service offerings; integrating diagnostic data into commercial value propositions can distinguish products in crowded therapeutic classes. Concurrently, investing in formulation versatility-such as palatable oral suspensions for companion animals and extended-release injectables for livestock-will improve adherence and meet diverse clinical needs.

From a supply perspective, diversifying sourcing through regional manufacturing partnerships and qualified contract manufacturers can reduce exposure to tariff and logistics volatility while shortening lead times. Commercially, companies should develop tailored go-to-market strategies for different channels, including omnichannel approaches for retail and online pharmacies, and service bundles for veterinary hospitals and distributors that incentivize stewardship-aligned prescribing. Finally, embedding environmental risk assessments and residue management into product lifecycle planning will address regulator and customer expectations, supporting long-term market acceptance and license-to-operate objectives.

Robust mixed-methods approach combining literature synthesis, primary expert interviews, and scenario mapping to ensure transparent and actionable market insights

The research synthesis underpinning these insights draws on a mixed-methods approach that combines systematic literature review, primary qualitative interviews, and structured stakeholder engagement. The literature review surveyed peer-reviewed clinical studies, regulatory guidance documents, and technical reports to capture contemporary scientific and safety considerations. Primary inputs were gathered through confidential interviews with veterinarians, pharmacovigilance experts, hospital procurement leads, contract manufacturers, and trade advisors to surface operational challenges and real-world adoption drivers.

Analytical techniques included cross-sectional thematic analysis of qualitative data to identify recurring market signals, triangulation of regulatory trends to assess evolving compliance expectations, and scenario mapping to evaluate the implications of trade policy shifts and resistance emergence. Data quality was maintained through source triangulation and expert validation rounds. The methodology emphasizes transparency in assumptions and traceability of insights, enabling readers to understand the evidence base and to adapt findings to their organization's strategic context.

Synthesis of strategic imperatives highlighting stewardship, innovation, and supply chain adaptability as the foundation for sustainable success in anthelmintic therapeutics

In conclusion, the anthelmintic drugs domain is at an inflection point where clinical necessity intersects with commercial and regulatory complexity. The interplay of emerging resistance, novel formulation opportunities, and changing trade dynamics necessitates proactive strategies that prioritize diagnostic integration, stewardship, and supply chain diversification. Regional variation in epidemiology and regulatory regimes requires bespoke market approaches that reflect local priorities while preserving global coherence in product positioning and evidence generation.

Organizations that harmonize scientific rigor with flexible commercial models will be best positioned to deliver both clinical value and sustainable growth. By focusing on targeted innovation, strengthened distribution partnerships, and data-driven stewardship, stakeholders can navigate near-term disruptions and build resilient pathways for long-term therapeutic relevance. These conclusions provide a pragmatic blueprint for aligning R&D, regulatory, and commercial activities to meet the evolving needs of clinicians, producers, and public health decision-makers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of ivermectin-oxantel combination therapies to combat resistant soil-transmitted helminths
  • 5.2. Adoption of point-of-care molecular diagnostics for rapid detection of multi-drug resistant helminth infections in livestock
  • 5.3. Emergence of plant-derived phytochemical anthelmintics as sustainable alternatives in aquaculture management
  • 5.4. Implementation of integrated mass drug administration campaigns targeting onchocerciasis and lymphatic filariasis co-endemic regions
  • 5.5. Investment in nanoformulation techniques to enhance bioavailability and efficacy of benzimidazole-based anthelmintics
  • 5.6. Regulatory approval pathways for novel macrocyclic lactone analogues designed to minimize environmental drug residues
  • 5.7. Expansion of precision dosing algorithms using pharmacogenomic data to optimize anthelmintic therapy in pediatric populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anthelmintic Drugs Market, by Drug Class

  • 8.1. Benzimidazoles
  • 8.2. Imidazothiazoles And Tetrahydropyrimidines
  • 8.3. Macrocyclic Lactones

9. Anthelmintic Drugs Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Food Producing Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep And Goat
    • 9.2.4. Swine
  • 9.3. Human
    • 9.3.1. Adults
    • 9.3.2. Pediatric

10. Anthelmintic Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Anthelmintic Drugs Market, by Formulation

  • 11.1. Injectable
  • 11.2. Oral Suspension
  • 11.3. Tablet

12. Anthelmintic Drugs Market, by Sales Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Distributors
  • 12.4. Veterinary Hospitals And Clinics

13. Anthelmintic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anthelmintic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anthelmintic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Boehringer Ingelheim GmbH
    • 16.3.3. Ceva Sante Animale S.A.
    • 16.3.4. Virbac S.A.
    • 16.3.5. Dechra Pharmaceuticals PLC
    • 16.3.6. Norbrook Laboratories Limited
    • 16.3.7. Aden Healthcare
    • 16.3.8. Bayer AG
    • 16.3.9. Cipla Limited
    • 16.3.10. Anikem Laboratories

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTHELMINTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GCC ANTHELMINTIC DR